Arturo LoAIza-Bonilla, Systemwide Chief of Hematology and Oncology at St. Luke’s University Health Network, and Co-Founder and Chief Medical AI Officer (CMAIO) of Massive Bio, shared a post on LinkedIn:
“The most effective lever health systems can pull is embedding clinical trial eligibility assessment directly into routine care workflows.
When trial matching is automated, guideline-anchored and triggered at key clinical decision points – such as diagnosis, progression or biomarker results – access scales naturally and more equitably.
Decentralized trials help, but the real unlock is operational integration that removes the cognitive and logistical burden from both clinicians and patients, ensuring trials are considered as care, not as an afterthought. The efforts of patient-centered trial activation using AI such as American Cancer Society’s ACS ACTS are key and the future.
–Arturo Loaiza-Bonilla, MD. System Chief of Hematology and Oncology at St. Luke’s University Health Network.”
Other articles featuring Arturo LoAIza-Bonilla on OncoDaily.